Skip to main content
SpringerLink
Log in

Clinical Efficacy and Prospects for Use of Pegylated Liposomal Doxorubicin in the Treatment of Ovarian and Breast Cancers

  • Published:
Drugs Aims and scope Submit manuscript

Summary

There is an urgent need for more active and better tolerated chemotherapy regimens for the treatment of advanced breast and ovarian cancers. Current therapeutic strategies in these malignancies include the use of moderately effective initial regimens that are usually accepted by patients. Tolerability considerations are especially important in the development of palliative regimens: retreatment for persistent or hormone-resistant disease must include quality-of-life analyses.

Pegylated liposomal doxorubicin (PLD) has demonstrated a better therapeutic index than free doxorubicin in murine solid tumours and human tumour xenografts in nude mice. In early clinical studies in patients with refractory ovarian cancer, PLD has produced high response rates (26%) and gratifyingly long response durations (8 to 21 + months after onset of therapy). Less mature data also suggest that PLD is active against breast cancer.

Information from these same clinical studies confirms the marked reduction in several toxicities associated with free doxorubicin, including nausea and vomiting, myelosuppression and cardiotoxicity. Alopecia is also markedly diminished. On the other hand, mucosal and skin toxicities appear to be more common with PLD.

PLD therefore offers the prospect of retaining activity, together with attenuated acute toxicity. In addition to facilitating the development of palliative regimens with better tolerability, the drug may lend itself to effective integration of chemotherapy with loco-regional therapies, utilisation in ‘maintenance’ regimens that are associated with an acceptable quality of life for the patient, and the avoidance of long term toxicities associated with treatment. Moreover, additional study of PLD in combination with other drugs and modalities may extend the use of the drug beyond palliation to the development of combination regimens with other drugs at conventional doses, and high doses with G-CSF support.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Muggia FM. Future of cancer chemotherapy with cisplatin. Semin Oncol 1989; 16Suppl. 6: 123–8

    PubMed  CAS  Google Scholar 

  2. Decker DG, Fleming TR, Malkasian GD, et al. Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma. Obstet Gynecol 1982; 60: 481–7

    PubMed  CAS  Google Scholar 

  3. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, et al. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 1987; 5: 1157–68

    PubMed  CAS  Google Scholar 

  4. Muggia FM. Cytoprotection: concepts and challenges. Supp Care Cancer 1994; 2: 380–4

    Article  Google Scholar 

  5. Garcia AA, Muggia FM. Activity of anthracyclines in refractory ovarian cancer: recent experience and review. Cancer Invest 1997; 15: 329–34

    Article  PubMed  CAS  Google Scholar 

  6. Allen TM. Liposomes: opportunities in drug delivery. Drugs 1997; 54(4): 8–14

    Article  PubMed  CAS  Google Scholar 

  7. McGuire WP, Hoskins W, Brady M, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage 3 and stage 4 ovarian cancer. New Engl J Med 1996; 334: 1–6

    Article  PubMed  CAS  Google Scholar 

  8. Muggia FM. Role of intraperitoneal consolidation in ovarian cancer. Isr J Obstet Gynecol 1996; 7 Suppl.: 17–22

    Google Scholar 

  9. Muggia FM. Overview of carboplatin: replacing, complementing, and extending the therapeutic horizons of cisplatin. Semin Oncol 1989; 16Suppl. 5: 1–7

    Google Scholar 

  10. Vermorken JB, Eisenhauer EA, Lu F, et al. Prognostic features of importance for phase II studies in platinum-pretreated ovarian cancer (OC) patients [abstract 355]. Proceedings of the VI International Conference on Anticancer Treatment. Paris, France: 1996 Feb: 130

  11. Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women (Pt 2). Lancet 1992; 339: 71–85

    Google Scholar 

  12. Fisher B, Redmond C, Legault-Poisson S, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumours responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B 16. J Clin Oncol 1990; 8: 1005–15

    PubMed  CAS  Google Scholar 

  13. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13: 2688–99

    PubMed  CAS  Google Scholar 

  14. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer. A randomised trial. J Clin Oncol 1995; 13: 2483–9

    PubMed  CAS  Google Scholar 

  15. Crown JP, Fennelly D. High-dose chemotherapy with peripheral blood progenitor autografting. In: Muggia FM, editor. Concepts, mechanisms and new targets for chemotherapy. Cancer Treatment and Research Series. Boston: Kluwer Academic Publishers, 1995: 209–26

    Chapter  Google Scholar 

  16. Formend SC, Lenz HJ, Dunnington G, et al. Initial p53 status as potential predictor for pathological complete response to the combination of 5FU and radiotherapy in locally advanced breast cancer [abstract 174]. Proc Am Soc Clin Oncol 1996; 15: 127

    Google Scholar 

  17. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of Pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New Engl J Med 1996; 335: 1785–91

    Article  PubMed  CAS  Google Scholar 

  18. Coates A, Gebski V, Stat M, et al. Improving the quality of life during chemotherapy for advanced breast cancer: a comparison of intermittent and continuous treatment strategies. N Engl J Med 1987; 317: 1490–5

    Article  PubMed  CAS  Google Scholar 

  19. Muggia FM. Managing breast cancer in an outpatient setting. Breast Cancer Res Treat 1992; 21: 27–34

    Article  PubMed  CAS  Google Scholar 

  20. Muggia FM, Braly PS, Brady MF, et al. Phase III of cisplatin (P) or paclitaxel (T), versus their combination in suboptimal stage III and IV epithelial ovarian cancer (EOC): Gynecologic Oncology Group (GOG) study no. 132. Proc Am Soc Clin Oncol 1997; 16: 352a

    Google Scholar 

  21. Muggia FM, Hainsworth J, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987–993

    PubMed  CAS  Google Scholar 

  22. Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995; 13: 1777–85

    PubMed  CAS  Google Scholar 

  23. Uziely B, Groshen S, Jeffers S, et al. Paclitaxel (Taxol) in heavily pretreated ovarian cancer: antitumor activity and complications. Ann Oncol 1994; 5: 827–33

    PubMed  CAS  Google Scholar 

  24. Chan S, Winterbottom L, Gardner S. Response to dexamethasone in patients with fluid retention after docetaxel [letter]. Lancet 1996; 347: 1486–7

    Article  PubMed  CAS  Google Scholar 

  25. Piccart MJ, Di Leo A, Awada A, et al. Docetaxel in the treatment of breast cancer: current status, ongoing trials and future directions. In: Calvo F, Crepin M, Madelenot H, editors. Breast cancer: advances in biology and therapeutics. Norwell MA: Kluwer Academic Publishers, 1996: 257–64

    Google Scholar 

  26. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis — correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1–8

    Article  PubMed  CAS  Google Scholar 

  27. Klauber N, Parangi S, Flynn E, et al. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitor 2-methoxyestradiol and Taxol. Cancer Res 1997; 57: 81–6

    PubMed  CAS  Google Scholar 

  28. Brooks PC, Montgomery AMP, Rosenfeild, et al. Integrin alpha (v) beta (3) antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157–61

    Article  PubMed  CAS  Google Scholar 

  29. DelaFlor-Weiss E, Uziely B, Muggia FM. Protracted drug infusions in cancer treatment: an appraisal of 5-fluorouracil, doxorubicin and platinums. Ann Oncol 1993; 4: 723–33

    PubMed  CAS  Google Scholar 

  30. Israel VK, Jeffers S, Bernai G, et al. Phase I study of Doxil (liposomal doxorubicin) in combination with paclitaxel. Proc Am Soc Clin Oncol 1997; 16: 239a

    Google Scholar 

  31. Safra T, Jeffers S, Groshen S, et al. Doxil (D) in platinum-refractory epithelial ovarian cancer (EOC): results from 3 consecutive phase I/II studies. Proc Am Soc Clin Oncol 1997; 16: 349a

    Google Scholar 

  32. Muggia FM, Amantea M, Jeffers S, et al. Doxil (doxorubicin in Stealth liposomes): a drug with a favorable therapeutic index in the management of refractory epithelial ovarian cancer. Cancer Invest 1997; 15Suppl. 1: 39–41

    Google Scholar 

  33. Rustin GJS, Nelstrop AE, McClean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to CA 125. J Clin Oncol 1996; 14: 1545–51

    PubMed  CAS  Google Scholar 

  34. Christian MC, Trimble EL. Salvage chemotherapy for epithelial ovarian carcinoma. Gynecol Oncol 1994; 55: S143–50

    Article  PubMed  CAS  Google Scholar 

  35. Ranson M, Carmichael J, O’Byrne K, et al. Treatment of advanced breast cancer with stealth liposomal doxorubicin (Caelyx): results of a multicenter phase II trial. J Clin Oncol 1997. In press

    Google Scholar 

  36. Gabizon A, Uziely B, Lotem M, et al. Doxil in patients with pretreated metastatic breast cancer (MBC): a dose-schedule finding study with pharmacokinetics. Proc Am Soc Clin Oncol 1997; 16: 147a

    Google Scholar 

  37. Bertelsen K, Kruhoffer A. What have we achieved in ovarian cancer? A comparison of survivals and resources in two different periods. Int J Gynecol Cancer 1995; 8: 148–55

    Article  Google Scholar 

  38. Meden H, Metz A, Monkeberg-Tun E. Quality of life of patients with ovarian cancer after surgery and chemotherapy. Onkologie 1994; 17: 50–6

    Article  Google Scholar 

  39. Taplin SH, Barlow W, Urban N, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995; 87: 417–26

    Article  PubMed  CAS  Google Scholar 

  40. Rubens RD. Key issues in the treatment of advanced breast cancer: expectation and outcomes. Pharmacoeconomics 1996; 9Suppl. 2: 1–7

    Article  PubMed  Google Scholar 

  41. Hutton J, Brown R, Borowitz M, et al. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics 1996; 9Suppl. 2: 8–22

    Article  PubMed  Google Scholar 

  42. Bonneterre J, Schraub S, Lecomte S, et al. Quality of life as an outcome in breast cancer: clinical application. Pharmacoeconomics 1996; 9Suppl. 2: 23–9

    Article  PubMed  Google Scholar 

  43. Buzdar AU, Hortobagyi GN, Frye D, et al. Second-line chemotherapy for metastatic breast cancer including quality of life issues. Breast 1996; 5: 312–7

    Article  Google Scholar 

  44. McQuellan RP, Muss HB, Hoffman SL, et al. Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. J Clin Oncol 1995; 13: 858–68

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. New York University Medical Center, New York, USA

    Franco M. Muggia

Authors
  1. Franco M. Muggia
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Muggia, F.M. Clinical Efficacy and Prospects for Use of Pegylated Liposomal Doxorubicin in the Treatment of Ovarian and Breast Cancers. Drugs 54 (Suppl 4), 22–29 (1997). https://doi.org/10.2165/00003495-199700544-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199700544-00006

Keywords

Search

Navigation